JP2024513494A5 - - Google Patents

Info

Publication number
JP2024513494A5
JP2024513494A5 JP2023561863A JP2023561863A JP2024513494A5 JP 2024513494 A5 JP2024513494 A5 JP 2024513494A5 JP 2023561863 A JP2023561863 A JP 2023561863A JP 2023561863 A JP2023561863 A JP 2023561863A JP 2024513494 A5 JP2024513494 A5 JP 2024513494A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
alkoxy
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513494A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023388 external-priority patent/WO2022216645A1/en
Publication of JP2024513494A publication Critical patent/JP2024513494A/ja
Publication of JP2024513494A5 publication Critical patent/JP2024513494A5/ja
Pending legal-status Critical Current

Links

JP2023561863A 2021-04-08 2022-04-05 がんの治療のためのprmt5阻害剤を使用する併用療法 Pending JP2024513494A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172643P 2021-04-08 2021-04-08
US63/172,643 2021-04-08
US202163253029P 2021-10-06 2021-10-06
US63/253,029 2021-10-06
PCT/US2022/023388 WO2022216645A1 (en) 2021-04-08 2022-04-05 Combination therapies using prmt5 inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024513494A JP2024513494A (ja) 2024-03-25
JP2024513494A5 true JP2024513494A5 (https=) 2025-04-14

Family

ID=81748438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561863A Pending JP2024513494A (ja) 2021-04-08 2022-04-05 がんの治療のためのprmt5阻害剤を使用する併用療法

Country Status (9)

Country Link
US (2) US12171765B2 (https=)
EP (1) EP4319753A1 (https=)
JP (1) JP2024513494A (https=)
KR (1) KR20230167050A (https=)
AU (1) AU2022254651A1 (https=)
CA (1) CA3214535A1 (https=)
IL (1) IL307393A (https=)
MX (1) MX2023011853A (https=)
WO (1) WO2022216645A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240208912A1 (en) * 2021-03-11 2024-06-27 Mirati Therapeutics, Inc. MTA-Cooperative PRMT5 Inhibitors
WO2023098439A1 (zh) * 2021-11-30 2023-06-08 上海和誉生物医药科技有限公司 一种吡唑衍生物,其制备方法和在药学上的应用
WO2023125540A1 (zh) * 2021-12-27 2023-07-06 南京明德新药研发有限公司 吡唑-1(2h)-酞嗪酮类化合物及其应用
CN119301101A (zh) * 2022-07-29 2025-01-10 四川科伦博泰生物医药股份有限公司 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
WO2024027703A1 (zh) * 2022-08-02 2024-02-08 上海艾力斯医药科技股份有限公司 一种prmt5抑制剂、其制备方法及应用
CN120265615A (zh) * 2022-11-29 2025-07-04 正大天晴药业集团股份有限公司 含有二氢酞嗪的化合物
WO2024177416A1 (ko) * 2023-02-22 2024-08-29 단국대학교 천안캠퍼스 산학협력단 Egfr 표적치료제 내성암 치료용 약학 조성물
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025157288A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和cdk4/6抑制剂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3268044A2 (en) * 2015-03-11 2018-01-17 The Broad Institute Inc. Prmt5 inhibitors for the treatment of cancer with reduced mtap activty
JP2021176819A (ja) 2018-07-31 2021-11-11 アステラス製薬株式会社 キナゾリン化合物を有効成分とする医薬組成物
IL290341B2 (en) 2019-09-12 2024-11-01 Mirati Therapeutics Inc Mta-cooperative prmt5 inhibitors
KR20220086628A (ko) * 2019-10-22 2022-06-23 루핀 리미티드 Prmt5 저해제의 약학적 조합물

Similar Documents

Publication Publication Date Title
JP2024513494A5 (https=)
JP2024513492A5 (https=)
CA2956628C (en) Pyridinylaminopyrimidine derivatives, preparation process and use thereof
CN103124729B (zh) 作为Axl抑制剂的药物活性化合物
ES2989617T3 (es) Moduladores de receptores de quimioquinas y usos de los mismos
JP2021523159A5 (https=)
JP2020517616A5 (https=)
JP2024502886A (ja) がんを処置及び/又は予防するためのsos1阻害薬の医薬組合せ
ES2857649T3 (es) Inhibidores de serina/treonina cinasa
ES2868748T3 (es) Compuesto de piridina
AU2023275712A1 (en) Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof
HRP20230472T1 (hr) Novi derivati hidroksikiseline, postupak njihove priprave i farmaceutski sastavi koji ih sadrže
KR102866565B1 (ko) Parp1 저해제 및 이의 용도
CA2752885A1 (en) Jak kinase modulating quinazoline derivatives and methods of use thereof
JP2009515988A5 (https=)
KR20170049604A (ko) Bub1 억제제로서의 벤질 치환된 인다졸
ES2585244T3 (es) Composiciones y métodos para modular una cinasa
TW201219383A (en) Chemical compounds
FR3008975A1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA3161339A1 (en) Cyclic compounds and methods of using same
CN111683662B (zh) 取代嘧啶类化合物及其药物组合物和治疗方法
CA3142088A1 (en) Compound used as kinase inhibitor and application thereof
ES2682270T3 (es) Combinación farmacéutica sinérgica para el tratamiento del carcinoma de células escamosas de cabeza y cuello
JP2018532786A5 (https=)
JP2014505662A5 (https=)